Glutathione Gene and Antioxidant Capacity | Decoding Inflammation

By Alberto Rivera, MD · 2026-05-05 · 5 min read

What Glutathione Actually Does

Glutathione, the tripeptide of glutamate, cysteine, and glycine, operates as the cell's primary reducing agent, electron donor, and detoxification cofactor simultaneously. In its reduced form (GSH), it neutralizes hydrogen peroxide, detoxifies reactive aldehydes, supports the regeneration of vitamins C and E, and anchors the entire glutathione peroxidase family of antioxidant enzymes.

The liver produces the largest quantities, but every cell synthesizes its own supply. The rate-limiting step is the activity of glutamate-cysteine ligase, encoded by GCLC and GCLM. Variants in these genes reduce enzymatic efficiency and lower the ceiling of intracellular glutathione that a cell can achieve regardless of substrate availability.

GSTP1 and the Detoxification Side

Glutathione S-transferase pi 1, encoded by GSTP1, conjugates glutathione to electrophilic toxins, enabling their excretion. The Ile105Val variant, rs1695, reduces the enzyme's catalytic efficiency by approximately 30 percent. In combination with GSTM1 and GSTT1 null genotypes, complete gene deletions that eliminate entire detoxification enzyme families, the result is a genome that both produces less glutathione and depletes what it produces more rapidly on every environmental toxic exposure it encounters.

A 2024 population study in Environmental Health Perspectives demonstrated that GSTP1 Ile105Val carriers in urban environments show accelerated GSH depletion under particulate matter exposure relative to wild-type carriers. The genome does not operate in a vacuum. Its vulnerabilities are expressed through environmental interaction.

The Supplementation Paradox

Oral glutathione supplementation faces a fundamental challenge: the peptide bond is cleaved in the gastrointestinal tract, delivering precursors rather than intact GSH. Liposomal and sublingual delivery formats improve bioavailability, but the ceiling remains genomically constrained. In carriers of GCLC rate-limiting variants, the upstream synthesis bottleneck persists regardless of delivery route.

The GENEFLAMMATION approach addresses this by mapping the full glutathione biosynthesis and utilization pathway, GCLC, GCLM, GSS, GPX1, GPX4, GSTP1, GSTM1, GSTT1, and building a supplementation protocol calibrated to the specific enzymatic deficits the genome reveals, rather than applying a uniform antioxidant intervention to a heterogeneous molecular problem.